LUCEMYRA® should be taken orally, four times per day, for the expected duration of withdrawal symptoms
Dosing for LUCEMYRA should be guided by symptoms and side effects
A lower starting dose can be considered for patients with less severe symptoms or patients who present with additional concerns such as advanced age, low weight, or poor tolerability
Usual LUCEMYRA starting dosage:
Three 0.18 mg tablets (0.54 mg) taken orally 4 times daily during peak withdrawal symptoms (generally, this is the first 5 to 7 days after the last use of an opioid)
 |
There should be 5 to 6 hours between each dose |
 |
The total daily dosage of LUCEMYRA should not exceed 2.88 mg (16 tablets) and no single dose should exceed 0.72 mg (4 tablets) |
 |
LUCEMYRA can be taken with or without food |
 |
LUCEMYRA treatment may be continued for up to 14 days as guided by symptoms |
In the prescription, include instructions for discontinuing LUCEMYRA1
Discontinue LUCEMYRA with a gradual dose reduction over a 2- to 4-day period
(e.g., reducing by 1 tablet per dose every 1 to 2 days)
LUCEMYRA was studied in phase I drug interaction studies with commonly used therapies for Opioid Use Disorder: buprenorphine, methadone, and oral naltrexone1
- LUCEMYRA and methadone both prolong the QT interval. ECG monitoring is recommended in patients receiving methadone and LUCEMYRA
- It is possible that oral naltrexone efficacy may be reduced if used concomitantly within 2 hours of LUCEMYRA
- This interaction is not expected if naltrexone is administered by non-oral routes
There are no contraindications associated with LUCEMYRA1
Reference
- LUCEMYRA® (lofexidine) [Prescribing Information]. USWM, LLC; 2020.
